Chlorogenic acid modulates gut microbiota and metabolites to alleviate intrahepatic cholestasis of pregnancy: Insights from 16S rRNA sequencing and metabolomics

Danli Ma, Yanwen Xu, Ruixia Liang, Qingju Meng, Yanli Liu, Danling Hu, Bin Zhu, Yongxia Zheng, Qiwei Luo · 2026

Read Chlorogenic acid modulates gut microbiota and metabolites to alleviate intrahepatic cholestasis of pregnancy: Insights from 16S rRNA sequencing and metabolomics by Danli Ma, Yanwen Xu, Ruixia Liang, Qingju Meng, Yanli Liu, Danling Hu, Bin Zhu, Yongxia Zheng, Qiwei Luo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13186075.txt.

Introduction

Danli Ma and co-authors test a plant compound against a liver disorder of pregnancy in rats, in a 2026 study. The disorder, cholestasis of pregnancy, blocks bile flow and endangers mother and baby, and the standard drug helps only modestly. Chlorogenic acid, found in coffee and many plants, guards the liver in other settings. Rats were given a hormone that mimics the disorder, then treated with rising doses of the compound.

Treatment lowered liver enzymes, bile acids, and bilirubin, and eased the liver damage seen under the microscope. It tuned key proteins that make and move bile, and strengthened the gut wall's sealing proteins. Gene and chemistry surveys showed the gut microbe mix recovering. Higher doses worked better. The authors propose the compound as a candidate therapy worth further study.

Catalog record

CREATORDanli Ma, Yanwen Xu, Ruixia Liang, Qingju Meng, Yanli Liu, Danling Hu, Bin Zhu, Yongxia Zheng, Qiwei Luo
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13186075

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Chlorogenic acid modulates gut microbiota and metabolites to alleviate intrahepatic cholestasis of pregnancy: Insights from 16S rRNA sequencing and metabolomics Authors: Danli Ma, Yanwen Xu, Ruixia Liang, Qingju Meng, Yanli Liu, Danling Hu, Bin Zhu, Yongxia Zheng, Qiwei Luo Published: 2026 ABSTRACT AbstractIntrahepatic cholestasis of pregnancy (ICP) is a liver disorder marked by impaired bile flow, elevated serum bile acids, and pruritus, posing significant risks to maternal and fetal health. Current treatments, including ursodeoxycholic acid, have shown limited efficacy, underscoring the need for more effective therapies. Chlorogenic acid (CGA), a polyphenolic compound with antioxidant, anti-inflammatory, and hepatoprotective properties, has shown promise in managing liver diseases, but its role in ICP remains poorly understood. This study investigated the therapeutic effects of CGA in a rat model of ICP induced by 17α-ethinylestradiol. CGA treatment significantly reduced liver enzyme levels, total bile acids, and bilirubin, while improving histopathological liver damage. CGA also modulated key proteins involved in bile acid synthesis and transport, including FXR, CYP7A1, NTCP, and BSEP. Additionally, CGA treatment improved intestinal barrier function by upregulating tight junction proteins, including ZO-1. Metabolomics and 16S rRNA gene sequencing revealed that CGA treatment restored gut microbiota balance in ICP rats. CGA demonstrated a dose-dependent response, with higher doses providing more pronounced therapeutic effects. These findings suggest that CGA alleviates ICP by regulating bile acid metabolism, improving liver function, and modulating the gut microbiome, highlighting its potential as an effective therapeutic option for managing ICP.Keywords: Intrahepatic cholestasis of pregnancy, Chlorogenic acid, Bile acid metabolism, Gut microbiota, Hepatoprotective effects Introduction Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that typically manifests in the second or third trimester. It is characterized by impaired bile flow in the liver, leading to the accumulation of bile acids in the bloodstream [1]. The incidence of ICP varies significantly across geographical regions and ethnic groups. In China, the prevalence of ICP is approximately 6.06% [2]. A recent systematic review and meta-analysis covering nearly 43 million pregnancies across 302 studies found the global prevalence of ICP to be approximately 2.9% (95% confidence interval [CI]: 2.5–3.3%), highlighting a notably higher incidence in Asian countries, while the prevalence tends to be lower in high-income nations, reflecting the substantial impact of socioeconomic and geographical factors on the occurrence of ICP [3]. The primary clinical features of ICP include elevated serum bile acid levels and unexplained pruritus, which are hallmark symptoms [4]. These symptoms generally resolve within 1–3 weeks of delivery. Of particular concern is the significantly increased risk of fetal death associated with ICP, which is notably higher than that in the general pregnant population. This risk is especially pronounced when the total serum bile acid (TBA) level exceeds 100 μmol/L [5]. Although ursodeoxycholic acid (UDCA) is the standard treatment for ICP, studies have shown that it does not significantly reduce the risk of fetal death [6]. This finding underscores the limitations of current treatment options and highlights the urgent need for more effective therapeutic strategies. Recent studies also suggest a potential association between early onset ICP and gestational diabetes mellitus, indicating that the pathogenesis of ICP may not only be related to liver and bile factors, but also to metabolic disturbances [7]. Therefore, the development of new therapeutic agents for ICP remains a critical and unresolved challenge in the field of obstetric care. Traditional Chinese Medicine has a long history of use owing to its therapeutic properties, especially in the treatment of liver-related conditions [8]. Chlorogenic acid (CGA), a traditional Chinese medicinal compound found in plants such as Coffea arabica and Echinacea purpurea, has attracted significant interest because of its potential pharmacological benefits [9]. Chlorogenic acid is a polyphenolic compound belonging to the cinnamate ester class and is known for its potent antioxidant, anti-inflammatory, and hepatoprotective properties [10]. It has traditionally been used as a bioactive ingredient in various liver conditions, including liver inflammation, fatty liver disease, and cholestasis-related disorders [11,12]. Research has demonstrated that chlorogenic acid possesses several pharmacological properties that contribute to its therapeutic potential, including its ability to reduce liver inflammation, enhance antioxidant defense, and improve liver enzyme function [13,14]. Particularly, CGA has been shown to regulate key enzymes involved in bile acid synthesis and metabolism, suggesting a beneficial role in improving bile flow and alleviating cholestasis symptoms [15]. In the context of ICP, a pregnancy-specific liver disorder characterized by elevated serum bile acids and pruritus, the anti-inflammatory effects of chlorogenic acid and its ability to modulate bile acid levels are promising candidates for ICP treatment [16]. However, although preclinical data support its potential therapeutic use, there is limited clinical evidence regarding its efficacy in treating ICP, and the exact mechanisms underlying its effects on liver function and cholestasis remain unclear. Further clinical investigations are needed to evaluate the effectiveness of chlorogenic acid as a treatment for ICP and clarify its pharmacological mechanisms. The gut microbiome has recently emerged as a critical regulator of bile acid metabolism, and its disruption has been linked to various liver diseases, including ICP [17]. Growing evidence suggests that an imbalance in the gut microbiota can significantly affect the synthesis, absorption, and enterohepatic circulation of bile acids, which are essential for maintaining liver function [18]. In the context of ICP, clinical studies have revealed notable differences in gut microbiota composition between women with ICP and healthy pregnant women, emphasizing the importance of microbial balance in liver health [19,20]. This dysbiosis may contribute to the pathophysiology of ICP by disturbing bile acid metabolism, leading to elevated serum bile acid levels, which is one of the defining characteristics of the disease. Additionally, the gut microbiota plays a key role in modulating immune responses and liver inflammation, which are central to the development of cholestasis [21]. Alterations in the microbiome can potentially exacerbate the inflammatory processes in the liver, thus accelerating the onset and progression of ICP [22]. Therefore, restoring a balanced microbiome may be critical for managing ICP, as it may help normalize bile acid metabolism, alleviate liver inflammation, and improve liver function. Recent studies have proposed that interventions aimed at modulating the gut microbiota, such as prebiotics, probiotics, or specific therapeutic agents, could offer novel treatment strategies for ICP and improve clinical outcomes [23]. Previous studies have shown that CGA can improve alcohol-induced liver injury in mice [14] and alleviate fructose-induced salt-sensitive hypertension in mice by regulating both gut microbiota and bile acid metabolism [24]. CGA may influence the intestinal microbiome of patients with ICP. Understanding how CGA modulates the gut microbiota could provide valuable insights into its mechanism of action in managing this condition. In our study, ICP was induced in Sprague-Dawley pregnant rats using 17α-ethinylestradiol. The therapeutic effects of CGA were assessed by measuring serum biochemical parameters and evaluating histopathological changes in the liver. To identify the differential metabolites across the experimental groups, an untargeted metabolomics approach was employed, and 16S rRNA sequencing was used to analyze the composition of the fecal microbiota. This study also investigated the impact of CGA on the farnesoid X receptor (FXR)/cholesterol 7 alpha-hydroxylase (CYP7A1)/sodium taurocholate co-transporting polypeptide (NTCP) signaling pathway and intestinal barrier function. These results contribute to a deeper understanding of the mechanisms underlying ICP and offer promising insights for the development of new therapeutic strategies for

Read the complete text